Recent studies have decoded the evolutionary origins and expanding capabilities of CRISPR systems, underpinning revolutionary gene editing applications. Research tracing Type V CRISPR-Cas systems revealed how functional RNA splitting transformed transposons into CRISPR immune components. Complementing this, new investigations highlight CRISPR's role in enhancing CAR T cell function to overcome limitations in leukemia and myeloma treatments, showcasing gene editing's potential to improve immunotherapies. These insights deepen understanding of CRISPR mechanics and facilitate next-generation therapies.